Arena, Suzhou in inflammation deal

Chinese company Suzhou Connect Biopharmaceuticals Ltd. said it received an exclusive, worldwide license from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) to develop and commercialize preclinical small mol...